Predictors of Grade ≥ 2 and Grade ≥ 3 Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Three-dimensional Conformal Radiotherapy
Overview
Affiliations
Unlabelled: Grade ≥ 3 radiation pneumonitis (RP) is generally severe and life-threatening. Predictors of grade ≥ 2 are usually used for grade ≥ 3 RP prediction, but it is unclear whether these predictors are appropriate. In this study, predictors of grade ≥ 2 and grade ≥ 3 RP were investigated separately. The increased risk of severe RP in elderly patients compared with younger patients was also evaluated.
Material And Methods: A total of 176 consecutive patients with locally advanced non-small cell lung cancer were followed up prospectively after three-dimensional conformal radiotherapy. RP was graded according to Common Terminology Criteria for Adverse Events version 3.0.
Results: Mean lung dose (MLD), mean heart dose, ratio of planning target volume to total lung volume (PTV/Lung), and dose-volume histogram comprehensive value of both heart and lung were associated with both grade ≥ 2 and grade ≥ 3 RP in univariate analysis. In multivariate logistic regression analysis, age and MLD were predictors of both grade ≥ 2 RP and grade ≥ 3 RP; receipt of chemotherapy predicted grade ≥ 3 RP only; and sex and PTV/Lung predicted grade ≥ 2 RP only. Among patients who developed high-grade RP, MLD and PTV/Lung were significantly lower in patients aged ≥ 70 years than in younger patients (p < 0.05 for both comparisons).
Conclusions: The predictors were not completely consistent between grade ≥ 2 RP and grade ≥ 3 RP. Elderly patients had a higher risk of severe RP than younger patients did, possibly due to lower tolerance of radiation to the lung.
Gunnarsson K, Movik L, Pettersson N, Back A, Nyman J, Hallqvist A Acta Oncol. 2024; 63:791-797.
PMID: 39415565 PMC: 11495145. DOI: 10.2340/1651-226X.2024.40576.
Chen K, Li S, Chen M, Jin Z, Sun X, Zhou S BMC Cancer. 2024; 24(1):257.
PMID: 38395838 PMC: 10893751. DOI: 10.1186/s12885-024-12001-6.
Mechanism and clinical application of thymosin in the treatment of lung cancer.
Liu Y, Lu J Front Immunol. 2023; 14:1237978.
PMID: 37701432 PMC: 10493777. DOI: 10.3389/fimmu.2023.1237978.
Rades D, Werner E, Glatzel E, Bohnet S, Schild S, Tvilsted S Cancers (Basel). 2023; 15(2).
PMID: 36672276 PMC: 9856605. DOI: 10.3390/cancers15020326.
Mukai-Sasaki Y, Liao Z, Yang D, Inoue T Front Oncol. 2023; 12:984364.
PMID: 36591530 PMC: 9797663. DOI: 10.3389/fonc.2022.984364.